For investors looking to balance the search for growth with some caution, the "Growth at a Reasonable Price" (GARP) or "Affordable Growth" strategy offers a sensible middle path. This method tries to find companies that are showing good and lasting business increase, but whose stock prices are not at extreme levels that assume all future gains. It looks for businesses with good basic operations, solid earnings and money management, to confirm the increase narrative rests on firm ground. One stock that recently appeared from this sort of filtering process is Neurocrine Biosciences Inc (NASDAQ:NBIX), a biopharmaceutical company concentrated on neuroscience.
A Good Growth Path
The central idea of an affordable growth strategy is, expectedly, growth. A company must show a clear capability to enlarge its business at a good speed. Neurocrine Biosciences does very well here, receiving a high Growth Rating of 9 out of 10 from ChartMill’s basic analysis system. This grade comes from both strong past results and good future estimates.
- Past Results: In the last year, the company increased its Earnings Per Share (EPS) by a notable 41.64%, while sales rose by 21.45%. This is not a single event; the average yearly EPS increase over recent years is 29.09%, with sales growing at a 22.29% yearly rate.
- Future Estimates: Experts predict this pace to keep going, with EPS estimated to grow at an average yearly rate of 26.83% in the next few years. Sales growth is also projected to stay good at over 10% each year.
This steady, double-digit increase in important money measures is exactly what growth-focused investors search for, giving a clear story of commercial success and market reach for its neurology and endocrinology products.
Price Assessment in Perspective
While growth is necessary, paying a sensible price for it is what shapes the GARP method. An expensive stock can hurt future gains even if the company performs well. Neurocrine’s Valuation Rating of 7 implies the market acknowledges its growth without giving it an extremely high cost.
A detailed view of the numbers shows a detailed situation:
- The stock’s Price/Earnings (P/E) ratio of 28.57 is about the same as the wider S&P 500 average.
- More significantly, when measured against its biotechnology industry group, which often sells at high costs because of growth hopes, Neurocrine seems more moderately priced. Its P/E ratio is less than 92% of the industry, and its Forward P/E ratio of 21.79 is less than 94% of similar companies.
- Other price multiples, like Enterprise Value to EBITDA and Price/Free Cash Flow, also point to a price that is interesting relative to the industry.
This perspective is key. The valuation grade shows that investors are not paying a common "biotech high price" for Neurocrine’s growth, possibly giving a more appealing risk/reward setup.
Supporting Basics: Earnings and Money Strength
Lasting growth cannot stand alone; it must be backed by a money-making business plan and a firm financial position. This is why filters for affordable growth include reviews for earnings and money strength, to steer clear of "growth without regard to cost" companies that could be weak. Neurocrine earns a 7 in both these areas.
Earnings is a definite positive. The company has very good margins, with a Profit Margin of 16.73% and an Operating Margin of 22.25%, each better than over 90% of the industry. Its returns on assets, equity, and invested capital are all graded in the high group of its field, verifying that its growth is changing effectively into investor gains.
Money Strength is similarly firm, with a notable feature being a financial statement with no borrowed money. This gives great operational freedom and takes away risk linked to interest costs or new borrowing. Along with good short-term money ratios (Current Ratio of 3.39) and a very sound Altman-Z score of 7.48, the company’s money situation is safe, letting it pay for continued research and sales work from a position of firmness.
Final Thoughts and More Study
Neurocrine Biosciences shows an example of the affordable growth idea. It joins a top-graded growth picture, pushed by good commercial results and a hopeful product development, with a price that is sensible both compared to the market and, importantly, inside its own high-growth field. This growth is supported by high earnings and a very strong financial statement with no debt, tackling main risk points that growth investors often meet.
The company’s basic picture, as described in its full ChartMill Basic Analysis report, displays an uncommon match of force across growth, price, earnings, and health measures. For investors using a GARP plan, such a mix is the main goal.
Neurocrine Biosciences was found using a particular Affordable Growth filter. Investors curious about finding other companies that match this strategy of acceptable growth, fair price, and solid basics can review the filter and its present findings here.
Disclaimer: This article is for information only and is not financial guidance, a suggestion, or an offer to purchase or sell any security. Investing includes risk, including the possible loss of the original amount. You should do your own study and talk with a certified financial consultant before making any investment choices.